Compare Dyne Therapeutics Inc. Common Stock (DYN) vs iShares MSCI China ETF (MCHI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs iShares MSCI China ETF — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while iShares MSCI China ETF trades at $51.33 (market cap $5.91B). The key difference: iShares MSCI China ETF is far larger — about 2.1× Dyne Therapeutics Inc. Common Stock's market cap, and Dyne Therapeutics Inc. Common Stock is more actively traded (3,341,579 versus 1,759,881). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and iShares MSCI China ETF for 65 Days on average.
| DYN | MCHI | |
|---|---|---|
Market Cap | $2.86B | $5.91B |
Volume | 3,341,579 | 1,759,881 |
Sector | Health | Broad Market / Factor |
52-Week High | $26.78 | $65.59 |
52-Week Low | $14.60 | $50.48 |
Typical Hold Time | 0 Days | 65 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
MCHI, the iShares MSCI China ETF, trades at $52.135, down 0.03% on the day with a bearish technical signal from moving averages. The ETF faces mixed sentiment amid China's economic challenges including industrial overcapacity and trade tensions, though corporate profits surged 26% in Q2 2026. Support and resistance cluster tightly around $52, indicating consolidation near current levels with neutral oscillator readings.
MCHI presents a valuation opportunity trading at a significant discount to historical averages versus US indices, but risks include China's regulatory uncertainty, global trade friction, and weak domestic consumption. The upcoming Trump-Xi summit on September 24 could provide catalysts through potential trade agreements, though protectionism concerns remain elevated for Chinese equity exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →
